Optimizing transitions from direct factor Xa inhibitors to unfractionated heparin therapy

Clicks: 1
ID: 319634
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #143 of 151 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 151 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Purpose Hospitalized patients taking direct factor Xa inhibitors (DFXaIs), such as apixaban and rivaroxaban, often need to be transitioned to unfractionated heparin (UFH). This transition is complicated by residual DFXaI activity, which can lead to anticoagulant stacking and possible increased bleeding risk. The guidance on this transition from the manufacturers does not account for interpatient variability in drug clearance and may not be appropriate for all hospitalized patients. Summary Residual DFXaI anticoagulation at the time of UFH initiation can result in a period of dual anticoagulation or anticoagulant stacking. This issue is identified most often when heparin is monitored using the anti–factor Xa assay as this assay is highly sensitive to the DFXaI. Several retrospective descriptive studies have reported supratherapeutic heparin levels (above 0.7 units/mL), which can last for days depending on the presence of patient-specific factors that reduce DFXaI clearance. The period of anticoagulant stacking has been associated with bleeding events. With the UFH anti–factor Xa assay detecting both anticoagulants, alternative methods are needed for heparin monitoring when transitioning from a DFXaI to UFH. Limited data describe alternative approaches that can be categorized as approaches that ignore residual DFXaI anticoagulation and ones that account for residual DFXaI anticoagulation. Observational data suggest that approaches that measure baseline residual DFXaI anticoagulation allow for a delay in UFH initiation and can reduce bleeding risk. The authors provide recommendations for hospitals or health systems to consider for optimizing management of the transition from DFXaI to UFH therapy. Conclusion Each hospital or health system should develop a structured approach for managing DFXaI to UFH transitions. Ideally, the transition should be managed by pharmacists and involve measurement of residual DFXaI anticoagulation to inform the timing of UFH initiation. Prospective studies are needed to better define best practices.
Reference Key
openalex_W7167338263 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Michael P. Gulseth, Corey Dinunno, Marc D. Smith, Maureen A. Smythe
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag202
URL
https://doi.org/10.1093/ajhp/zxag202
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.